ArticleNature medicine2026
Nature Medicine Commission on dialysis policy in low- and middle-income countries.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Outcomes and Trade-offs of Thailand's 2022 Patient-Choice Dialysis Policy Reform.Kidney international reports · 2026Article
- Strengthening kidney care through evidence-informed participatory policymaking.Nature reviews. Nephrology · 2026Article
- When access outpaces ethics: reflections on dialysis expansion and health system integrity.Nature reviews. Nephrology · 2026Article
- PNI, CONUT, and GNRI for predicting treatment failure in peritoneal dialysis-associated peritonitis: a two-center retrospective study.Frontiers in nutrition · 2026Article
- The way home: a scoping review of public health interventions to increase the utilization of home dialysis in chronic kidney disease patients.BMC nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global demand for kidney replacement therapy (KRT) continues to increase, yet access remains limited in many low- and middle-income countries. Thailand has been recognized for integrating a sustainable KRT delivery model into its Universal Health Coverage scheme through a peritoneal dialysis-first ('PD-First') policy adopted in 2008. In 2022, the policy was revised to allow individuals to choose between hemodialysis or peritoneal dialysis as their first-line treatment. The intention was to improve patient choice and avoid high out-of-pocket costs, but the policy produced unintended consequences for the health system and patients. A Commission was convened to first assess the impact of the policy change and provide policy recommendations to the Thai government and, second, provide lessons for countries working to expand equitable access to KRT within national universal health coverage frameworks. Drawing on empirical data, the Commission-composed of Thai and international multidisciplinary experts-employed a structured deliberative process to inform policy interventions. The process and findings underscore the importance of participatory policymaking, underpinned by evidence and a systematic process, and monitoring and evaluation in managing complex policy transitions.
Indexed as
Identifiers
41566046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.